Literature DB >> 51345

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy.

R M Galbraith, A L Eddleston, R Williams, A J Zuckerman.   

Abstract

In three patients with malignant disease HBsAg was detected in the serum at least 6 months before the development of acute hepatitis type B, which in each case followed a fulminant course to death. It is suggested that suppression of the normal immunological responses to hepatitis-B viral antigens by cytotoxic drug therapy permitted widespread infection of hepatocytes. Subsequently, upon withdrawal of these drugs, recovery of immunocompetence resulted in rapid destruction of all infected hepatocytes and massive liver damage. Screening for HBsAg before cytotoxic drug therapy, careful monitoring of liver function during its withdrawal, and prompt treatment with corticosteroids should abnormalities occur may prevent this unfortunate sequence of events.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 51345     DOI: 10.1016/s0140-6736(75)90897-1

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  52 in total

Review 1.  Occult hepatitis B: clinical implications and treatment decisions.

Authors:  Paul Schmeltzer; Kenneth E Sherman
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

2.  Activation of hepatitis C virus following immunosuppressive treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Kanamori; F Kodama; H Okamoto
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

3.  Reactivation of precore mutant hepatitis B virus leading to fulminant hepatic failure following cytotoxic treatment.

Authors:  M Yoshiba; K Sekiyama; F Sugata; H Okamoto; K Yamamoto; S Yotsumoto
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

4.  S-phase arrest after vincristine treatment may promote hepatitis B virus replication.

Authors:  Lei Xu; Zeng Tu; Ge Xu; Jie-Li Hu; Xue-Fei Cai; Xing-Xing Zhan; Yu-Wei Wang; Yuan Huang; Juan Chen; Ai-Long Huang
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 5.  Viral hepatitis.

Authors:  J Y Lau; G J Alexander; A Alberti
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

6.  Antiviral treatment in chronic infection with hepatitis B virus.

Authors:  G Alexander; R Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1986-04-05

7.  Acute exacerbation of hepatitis due to reactivation of hepatitis B virus with mutations in the core region after chemotherapy for malignant lymphoma.

Authors:  T Sato; J Kato; J Kawanishi; K Kogawa; M Ohya; S Sakamaki; Y Niitsu
Journal:  J Gastroenterol       Date:  1997-10       Impact factor: 7.527

8.  The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma.

Authors:  Jawad Ahmad; John Rhee; Brian I Carr
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy.

Authors:  D Francisci; F Falcinelli; E Schiaroli; M Capponi; B Belfiori; L Flenghi; F Baldelli
Journal:  Infection       Date:  2009-11-10       Impact factor: 3.553

10.  Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B.

Authors:  I L Woolf; N El Sheikh; H Cullens; W M Lee; A L Eddleston; R Williams; A J Zuckerman
Journal:  Br Med J       Date:  1976-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.